Herpes Simplex News and Research

RSS

Herpes simplex is a viral disease caused by herpes simplex viruses; both herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) cause herpes simplex. Infection with the herpes virus is categorized into one of several distinct disorders based on the site of infection.

GSK launches Medivir's Xerclear for OTC use in Europe

Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.

8 Feb 2012

New NIST clinical SRM can help in accurate CMV detection and treatment

A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.

12 Jan 2012

Investigational HSV vaccine shows promise against two genital herpes diseases

An investigational vaccine protected some women against infection from one of the two types of herpes simplex viruses that cause genital herpes, according to findings in the New England Journal of Medicine.

5 Jan 2012

Researchers identify first gene associated with frequent herpes-related cold sores

A team of researchers from the University of Utah and the University of Massachusetts has identified the first gene associated with frequent herpes-related cold sores.

1 Dec 2011

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

NCI awards UAB $2.3M brain-tumor SPORE grant

The UAB Comprehensive Cancer Center and the UAB Division of Neurosurgery have been awarded a prestigious SPORE, or Specialized Program of Research Excellence, grant from the National Cancer Institute for $2.3 million over three years to conduct research and develop new therapies to treat brain tumors.

28 Oct 2011

C21orf91 gene associated with susceptibility to herpes simplex labialis

Investigators have identified a human chromosome containing a specific gene associated with susceptibility to herpes simplex labialis (HSL), the common cold sore.

28 Oct 2011

Tenofovir gel shows promise against HSV infection

HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.

20 Oct 2011

HSV1 drugs could slow progression of Alzheimer's disease

Antiviral drugs used to target the herpes virus could be effective at slowing the progression of Alzheimer's disease (AD), a new study shows.

From The University of Manchester 18 Oct 2011

FDA clears BioHelix IsoAmp HSV molecular diagnostic assay

BioHelix Corporation has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company's first molecular diagnostic assay, the IsoAmp HSV Assay. The diagnostic test is intended for the detection of Herpes Simplex Virus (HSV1 & HSV2) in genital and oral lesion specimens from symptomatic patients.

18 Oct 2011

USAID award supports study of SILCS diaphragm plus tenofovir gel on HIV, HSV

USAID awarded CONRAD a five year project with a $2 million ceiling to focus on testing the safety and effectiveness of the SILCS diaphragm, the one-size-fits-most contraceptive barrier, combined with tenofovir gel -- the only topical product proven to prevent the acquisition of HIV and Herpes Simplex Virus.

14 Oct 2011

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

DNA vaccine development company Coridon Pty Ltd. today announced that it had successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with outstanding results. The company will now look to progress the program into clinical studies.

10 Oct 2011

Isconova expands Matrix M collaboration with Genocea to treat infectious diseases

Isconova AB, a leading international vaccine adjuvant company and Genocea Biosciences, Inc., a vaccine discovery and development company pioneering a new class of T cell‐based vaccines, today announced the expansion of their collaboration granting Genocea the right to use Isconova's Matrix M in vaccines targeting two additional diseases.

23 Aug 2011

DNA vaccine developer Coridon in U.S. collaboration

DNA vaccine development company Coridon Pty Ltd. today announced that it has entered into a research collaboration agreement with The Ohio State University to progress its Epstein Barr Virus (EBV) project.

19 Jul 2011

Most cases of facial nerve paralysis in children can be treated successfully

A half-paralyzed face with a motionless, drooping side can be alarming at any age, but when it occurs in a child it can be especially devastating.

30 Jun 2011

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).

29 Jun 2011

New 3D herpes infection model brings hope

Herpes infections on the lips, in the eyes or on the nose are painful, long-lasting and unpleasant. A new 3D herpes infection model brings hope: active ingredients and new treatments can be reliably tested with this model. Animal tests could soon be a thing of the past.

27 Jun 2011

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir's unique cold sore treatment Xerclear in China and Hong Kong.

23 Jun 2011

Epstein-Barr virus might cause multiple sclerosis, study confirms

The Epstein-Barr (EVB) virus -belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus- is one of the environmental factors that might cause multiple sclerosis, a condition affecting the central nervous system, which causes are unknown.

18 May 2011